Somatic mutations in Nucleophosmin 1 or NPM1 gene (NPM1MT) are earlier driver hits in leukemogenesis and one of the most commonly identified genetic abnormalities in de novo acute myeloid leukemia (AML; ~30% of cases) [1] The distinct molecular and clinical features of NPM1MT AML led to its recognition as a separate entity in the 2017 World Health Organization (WHO) classification of myeloid neoplasms [2]. This evidence concerns the gene NPM1 and myeloid neoplasm.